| Pharmaceutical Information |
| Drug Name |
Secnidazole |
| Drug ID |
BADD_D02512 |
| Description |
Secnidazole is a second-generation 5-nitroimidazole antimicrobial that is structurally related to other 5-nitroimidazoles including [DB00916] and [DB00911], but displays improved oral absorption and longer terminal elimination half-life than antimicrobial agents in this class [A27210]. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria and protozoa. In September 2017, FDA granted approval to secnidazole under the market name Solosec as a single-dose oral treatment for bacterial vaginosis, which is a common vaginal infection in women aged 15 to 44 years. The antimicrobial therapy is only intended to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria [FDA Label]. |
| Indications and Usage |
Indicated for the treatment of bacterial vaginosis in adult women . |
| Marketing Status |
Not Available |
| ATC Code |
P01AB07 |
| DrugBank ID |
DB12834
|
| KEGG ID |
D07353
|
| MeSH ID |
C016724
|
| PubChem ID |
71815
|
| TTD Drug ID |
D0V5IW
|
| NDC Product Code |
14799-2008; 11014-0236; 27437-051; 49964-0047; 71052-367 |
| Synonyms |
secnidazole | 1-(2'-hydroxypropyl)-2-methyl-5- nitroimidazole | 14,539 RP | Secnol | Sabima | Secnidal | Solosec | Minovag |
|
| Chemical Information |
| Molecular Formula |
C7H11N3O3 |
| CAS Registry Number |
3366-95-8 |
| SMILES |
CC1=NC=C(N1CC(C)O)[N+](=O)[O-] |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
